Celcuity Inc.

08/12/2022 | Press release | Archived content

A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2 advanced breast cancer previously treated with a CDK4/6 inhibitor plus a[...]